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The	fluoropyrimidine	drug	fluorouracil	(FU)	is	one	
of	 the	most	 frequently	prescribed	chemotherapeu-
tic	drugs	 for	 the	curative	and	palliative	 treatment	of	
patients	with	breast,	gastrointestinal,	head	and	neck	
cancer	[1].	The	combination	of	FU	with	other	antican-
cer	agents	such	as	cyclophosphamide	and	metho-
trexate	(CMF)	has	been	extensively	used	for	cancer	
chemotherapy.	Randomized	clinical	trial	revealed	that	
adjuvant	CMF	 therapy	significantly	 improved	overall	
survival	and	 relapse-free	survival	 for	breast	cancer	
patients	who	 received	CMF	 therapy	compared	with	
those	who	did	not	[2].	Recently,	FU	based	therapy	has	
been	employed	in	primary	neoadjuvant	chemotherapy	
for	 patients	 before	 breast-conserving	 treatment	
[3,	4].	Successful	tumor	downstaging	by	neoadjuvant	
chemotherapy	has	been	associated	with	 increased	
rates	of	breast-conserving	therapy	and	shows	better	
long-term	outcomes	[5].	Significant	variability	in	the	
efficacy	of	chemotherapy	is	observed	in	breast	cancer	
patients.	The	sensitivity	of	cancer	drug	treatment	 is	
essential	 for	determining	the	most	suitable	strategy	
for	individual	cancer	patients.	However,	there	are	no	
standard	tools	for	prediction	of	a	patient’s	tumor	re-
sponse	to	chemotherapy.	
The	 identification	of	molecular	factors	associated	
with	either	responsiveness	or	resistance	to	FU	chemo-
therapy	is	increasingly	being	recognized	as	an	important	
field	of	study.	Dihydropyrimidine	dehydrogenase	(DPD)	
is	the	initial	and	rate-limiting	enzyme	in	the	catabolism	
of	FU	[6],	DPD	degrades	FU	 to	 fluoro-dihydrouracil.	
Pharmacokinetic	evaluation	has	 further	shown	 that	
DPD	catabolizes	>	80%	of	and	administered	dose	of	
FU,	 thereby	determining	 the	amount	of	FU	available	
for	anabolism	[7].	Early	analyses	of	human	tumor	cell	
xenografts	showed	a	wide	range	of	DPD	enzymatic	ac-
tivity	among	various	malignant	lesions	[8–10]. �arious	 	
human	cancer	cell	line	studies	demonstrated	that	DPD	
expression	is	inversely	correlated	with	FU	response	[11,	
12].	Animal	study	revealed	that	human	tumor	xenografts	
expressing	low	levels	of	DPD	mRNA	and	DPD	activity	
showed	a	significantly	better	response	to	FU	than	tu-
mors	with	high	DPD	mRNA	level	of	DPD	activity	[13].	
These	basic	studies	suggested	that	the	intra-tumoral	
levels	of	DPD	may	be	an	important	factor	for	predicting	
the	response	of	clinical	tumors	to	FU.
�ery	few	studies	have	investigated	the	relationship	
between	DPD	expression/activity	and	the	effect	of	FU	
based	chemotherapy	for	primary	gastric	cancer,	and	
the	conclusions	are	 still	 controversial	 [14–16].	We	
assume	that	the	controversial	results	may	be	partially	
due	 to	bias	 from	 treatment	 strategy	 including	sur-
gery	and	postoperative	adjuvant	radio-	or	hormonal	
treatment.	To	exclude	the	surgical	and	postoperative	
interventions,	we	performed	two	prospective	studies:	
(A)	The	histoculture	drug	response	assay	(HDRA)	[17]	
was	performed	 for	surgically	 resected	 fresh	breast	
tumor,	 intra-tumoral	DPD	activity	was	assessed	and	
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compared	with		FU	HDRA	chemosensitivity;	(B)	Clinical	
response	was	evaluated	for	a	cohort	of	breast	cancer	
patients	 received	 two	cycles	of	 FU	based	primary	
chemotherapy	before	operation,	DPD	expression	was	
compared	with	FU-based	chemosensitivity.
MAtERIALS AND MEtHODS
Patients and samples. Two	groups	of	operable	
primary	invasive	breast	carcinomas	were	included	in	our	
current	in �i���	and	in �i��	FU	chemosensitivity	studies.	
The	in	vitro	group	consisted	of	54 invasiveductalcarcino-	 	 	
mas.	None	of	the	patients	received	chemotherapy	or	ir-
radiation	therapy	prior	to	the	surgery.	Surgically	resected	
breast	cancer	 tissues	were	quickly	divided	 into	 three	
samples:	one	was	fixed	in	10%	buffered	formaldehyde	for	
pathological	diagnosis,	one	was	submitted	for	DPD	en-
zyme	activity	measurement,	and	one	for	HDRA	[17].	The	
in �i��	group	consisted	of	81	invasive	ductal	carcinomas	
enrolled	in	a	clinical	trial.	Before operation, core needle	 	 	 	
biopsy	was	performed	to	obtain	tissue	for	pathological	
diagnosis	and	immunohistochemistry	analysis,	and	all	
patients	were	scheduled	to	two	cycles	of	CMF	treatment.	
All	tumor	samples	were	collected	with	consent	for	tissue	
donation	and	local	research	ethics	committee	approval	
for	use	of	the	tissue	surplus	to	diagnostic	requirements	
for	cellular	and	molecular	assays.
Measurement of DPD enzyme activity. DPD	
activity	was	determined	using	a	catalytic	assay	accord-
ing	to	the	method	described	by	Ikenaka	et	al.	[7]	with	
modification.	Breast	cancer	tissues	were	homogenized	
in	four	volumes	of	50	mM	of	Tris-HCl	(pH	8.0)	containing	
5	mM	of	2-mercaptoethanol,	25	mM	of	KCl,	and	5	mM	
of	MgCl2.	After	homogenization,	the	sample	was	centri-
fuged	at	105,000	g	for	60	min	at	4	°C.	The	supernatant	
cytosol	layer	was	collected	as	the	enzyme	source	for	the	
measurement	of	DPD	activity.	Microspin	G-25	column	
(Amersham	Biosciences,	Piscataway,	NJ)	was	used	to	
remove	internal	substrate	including	racil	and	thymine.	
The	remaining	cytosolic	fraction	was	frozen	and	stored	
at	–80	 °C	until	analysis.	The	assay	mixture	(0.25	ml)	
consisted	of	50	mM	Tris-HCl	(pH	8.0),	10	mM	MgCl2,	25	
mM	NaF,	50	mM	nicotinamide,	5	mM	ATP,	1	mM	NADPH,	
[6-3H]	5-FU	(0.2	mCi,	20	mM),	and	0.1	ml	of	the	enzyme	
extract.	The	mixture	was	incubated	for	30	min	at	37	°C,	
and	the	reaction	was	stopped	by	heating	at	100	°C	in	a	
water	bath.	After	centrifugation	at	3000	rpm,	the	su-
pernatant	(0.1	ml)	was	treated	with	0.01	ml	of	2M	KOH	
for	30	min	at	room	temperature.	Then,	the	mixture	was	
treated	with	0.005	ml	of	2M	PCA	and	centrifuged.	A	20ml	
aliquot	of	the	supernatant	was	taken	and	spotted	onto	
a	thin-layer	chromatography	plate	(Merck,	Whitehouse	
Station,	NJ)	and	developed	with	a	mixture	of	chloroform,	
methanol,	and	acetic	acid	(17	:	3	:	1,	v/v/v).	The	spots	
of	2-fluoro-alanine	and	2-fluoro-ureidopropionic	acid,	
FU	degradation	products,	were	scraped	into	vials	and	
mixed	with	10	mL	of	ACS-II	scintillation	fluid	(Amersham,	
Buckinghamshire,	UK).	The	radioactivity	was	measured	
in	a	Wallac	1410	liquid	scintillation	counter	(Pharmacia,	
Uppsala,	Sweden).	Internal	controls	were	used	to	com-
pare	assays.
Immunohistochemistry.	 For	 the	 immunohisto-
chemical	study,	4	µm	thick	sections	on	silane-coated	
slides	were	 dewaxed	with	 xylene	 and	 rehydrated	
through	a	graded	alcohol	series.	Then,	endogenous	
peroxidase	activity	was	blocked	in	absolute	methanol	
solution	containing	0.3%	hydrogen	peroxide	for	35	min	
and	the	slides	were	washed	in	10	mM	phosphate-buffe-
red	saline	 (PBS),	pH	7.4.	For	antigen	retrieval,	 they	
were	immersed	in	1mm	citrate-phosphate	buffer,	and	
microwaved	at	100	°C	for	15	min.	After	the	buffer	had	
cooled,	10%	fetal	serum	was	reacted	with	the	slides	
for	15	min	to	eliminate	non-specific	immunostaining.	
The	sections	were	then	incubated	with	anti-DPD	poly-
clonal	antibodies	[18]	overnight	at	4	°C	in	a	humidified	
chamber.	Biotinylated	goat	anti-rabbit	IgG	was	applied	
as	a	secondary	antibody	for	20	min	at	room	tempera-
ture,	followed	by	streptavidin-biotinylated	peroxidase	
complex	for	20	min	at	room	temperature.	Peroxidase	
activity	was	visualized	with	a	diaminobenzidine	as	the	
chromogen.	Replacement	of	the	primary	antibody	with	
PBS	was	used	as	a	negative	control.	Immunoreactivity	
in	the	cytoplasm	of	cancer	cells	was	observed	to	evalu-
ate	DPD.	When	more	than	25%	of	the	cancer	cells	were	
stained,	the	specimen	was	defined	as	positive.	
HDRA.	HDRA	was	conducted	according	to	previous	
report	 [19].	Briefly,	FU	was	dissolved	 in	RPMI-1640	
medium	(Sigma,	St.	Louis,	MO)	containing	20%	fetal	
bovine	serum	(FCS,	lansa,	Mexico),	penicillin-strep-
tomycin-amphotericin	B	(Gibco;	100	IU/ml,	100	µg/ml	
and	0.25%	µg/ml,	 respectively),	 and	1	ml	 solution	
per	well	was	poured	onto	a	24-well	palate.	The	cutoff	
concentration	used	to	distinguish	in �i��� sensitivity	and	
resistance	was	300	µg/ml,	which	was	appropriate	to	
the	plasma	level	achieved	in �i��	[19].	After	the	incuba-
tion	for	7	days,	100	µl	of	0.2%	MTT	(Sigma)/phosphate	
buffered	saline	 (PBS)	solutions,	containing	50	mM	
sodium	succinate,	was	added	to	each	well.	After	the	
plates	were	incubated	for	a	further	16	h,	the	medium	
was	 removed	 from	each	well,	 and	0.5	ml	dimethyl	
sulfoxide	(DMSO)	per	well	was	added	to	extract	MTT-
formazan.	After	2	h,	100	µl	solution	was	extracted	from	
each	well,	transferred	to	96-well	multiplate,	and	their	
absorbance	was	read	by	microplate	reader	at	540	nm	
with	a	reference	of	630	nm.	The	inhibition	index	(I.I.)	
was	calculated	using	the	formula: I.I.	=	(1-T/C)	x	100,	
where	T	is	mean	absorbency	of	the	treated	wells	per	
1	g	tumor,	and	C	is	mean	absorbance	of	the	control	
wells	per	1	g	tumor.		As	reported	previously,	the	cut-off	
I.I.	of	60%	was	employed	for	our	study	[20].	
FU-based chemotherapy and evaluation.	Two	
cycles	of	CMF	(cyclophosphamide,	methotrexate	and	
fluorouracil)	were	used	for	patients	in	this	group.	Tumor	
response	was	determined	by	palpation	after	two	cycles	of	
treatment.	If	the	tumor	size	decreased	less	than	50%,	pa-
tients	was	evaluated	as	resistante	to	the	chemotherapy,	if	
the	tumor	size	decreased	more	than	50%,	the	response	
were	defined	as	sensitive	to	the	treatment.
Statistical analysis.	A	computer	program	package	
(Stat�iew	5.0,	Abacus	Concepts,	Berkeley,	CA,	USA)	
was	used	for	all	statistical	testing	and	management	of	
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the	database.	Non-parametric	Mann	—	Whitney	U-test	
was	used	to	compare	median	values	between	sensi-
tive	and	resistant	groups	for	in	vitro	chemosensitivity	
study.	For	in	vivo	study,	chi-square	test	was	used	to	
test	 the	 relationship	between	DPD	expression	and	
FU-based	chemosensitivity.	A	p-value	less	than	0.05	
was	considered	statistically	significant.
RESuLtS
Association between in vitro FU chemosen-
sitivity and DPD Enzyme Activity.	With	 the	cut-
off	I.I.	 of	60%,	18	out	of	 the	54	 (33.33%)	patients	
were	sensitive	 to	FU.	The	DPD	enzyme	activity	was	
56.11	±	8.45	in	the	chemosensitive	group,	and	77.44	±	
5.97	pmol/mg	per	min	in	the	chemoresistant	group.	As	
shown	in	Fig.	1,	DPD	enzyme	activity	was	significantly	
lower	in	the	sensitive	group	than	resistant	group	(p	<	
0.0442).	
Fig. 1. Correlation	between	 intratumoral	DPD	activity	and	FU	
in �i���	chemosensitivity
Association between in vivo FU-based chemo-
sensitivity and DPD expression.	With	 two	cycles	
of	CMF	chemotherapy,	39	out	of	81	(48.15%)	tumors	
were	evaluated	to	be	sensitive	to	the	treatment	and	42	
(51.85%)	were	resistant.	According	to	immunostain-
ing,	44	out	of	81	(54.32%)	tumors	were	evaluated	as	
immunopositive	for	DPD,	and	37	(45.68%)	were	im-
munonegative	(Fig.	2).	As	shown	in	Table,	the	tumors	
with	positive	DPD	expression	were	resistant	to	FU,	and	
the	tumors	with	low	DPD	expression	were	sensitive	to	
FU	(p	<	0.0001).	
Fig. 2. Immunohistochemical	staining	of	breast	cancers	using	
anti-DPD	polyclonal	antibody.	The	tumor	cells	showed	diffuse	
cytoplasm	staining	for	anti-DPD	(x	400)
Table. Relationship between DPD expression and response to FU-based 
chemotherapy
DPD In vivo chemosensitivitysensitive resistant p value
Negative 29 8 < 0.0001
Positive 10 34
DIScuSSION
Chemotherapy	is	one	of	the	extremely	effective	mo-
dalities	of	breast	cancer	therapy	before	and/or	after	op-
eration.	No	single	regimen	has	been	demonstrated	to	be	
effective	in	100%	of	patients	even	with	the	same	tumor	
type.	Accurate	prediction	of	an	individual	patient’s	drug	
response	is	an	important	prerequisite	of	personalized	
medicine.	Therefore,	there	is	a	great	need	to	identify	
biological	marker(s)	that	can	predict	response	or	re-
sistance	to	chemotherapy	[21].	FU	is	one	of	the	most	
frequently	prescribed	chemotherapeutic	drugs.	
The	HDRA	may	be	an	appropriate	method	for	the	cul-
ture	of	breast	cancer	since	it	allows	the	interstitial	cells,	
which	occupy	the	major	portion	of	the	tumor	in	breast	
cancer,	to	be	cultured	in	their	natural	three-dimensional	
architecture	with	the	cancer	cells	[22].	The	HDRA	che-
mosensitivity	results	predict	clinical	outcomes	with	high	
sensitivity	in	cancers	of	head	and		neck,	stomach,	colon,	
urinary	tract,	ovary,	and	breast	[23–28].	In	the	present	
study,	HDRA	was	performed	on	54	samples.	DPD	ac-
tivity	was	measured	by	using	a	catalytic	assay	[7].	We	
correlated	the	result	of	FU	sensitivity	in	HDRA	and	DPD	
activity	in	tumor	tissue	and	found	that	decreased	DPD	
activity	was	associated	with	FU	sensitivity.	Our	result	is	
consistent	with	the	finding	from	a	previous	study	[20].	
We	further	analyzed	if	intra-tumoral	DPD	expression	was	
correlated	with	 in �i��	chemosensitivity	in	81	patients	
who	received	two	cycles	of	FU-based	chemotherapy.	
As	the	results,	decreased	DPD	expression	was	closely	
related	with	the	early	response	to	preoperative	chemo-
therapy.	Prediction	of	 treatment	effect	might	help	 to	
exclude	patients	with	a	low	probability	of	a	treatment	
benefit	 and	 improve	 the	benefit/risk	 ratio	 in	breast	
cancer	patients	receiving	neoadjuvant	chemotherapy.	
Based	on	our	current	study,	DPD	may	be	a	promising	
molecular	maker	 to	 identify	patients	with	 lower	DPD	
expression	for	FU-based	chemotherapy.	
Interestingly,	there	were	shown	different	modes	of	
action	of	FU-based	drugs	(tegafur	+	uracil	[UFT],	tega-
fur	+	gimeracil	+	oteracil	[S-1],	5'-deoxy-5-fluorouri-
dine	[5'-DFUR],	and	N4-pentyloxycarbonyl-5'-deoxy-
5-fluorocytidine	[capecitabine]),	as	well	as	three	other	
drugs	 (cisplatin	 [CDDP],	 irinotecan	hydrochloride	
[CPT-11],	and	paclitaxel)	on	genes	expression	pro-
files	which	correlated	with	the	sensitivity	of	30	human	
tumor	xenografts	in	the	recent	study	[29].	DPD	mRNA	
expression	profiles	of	the	tumors	showed	a	significant	
negative	correlation	with	chemosensitivity	to	all	of	the	
FU	based	drugs	except	for	S-1.	S-1	has	recently	been	
developed,	which	consists	of	tegafur	(FT),	5-chloro-2,	
4-dihydroxypyridine	(CDHP),	and	potassium	oxonate	
(Oxo)	in	a	molar	ratio	of	1	:	0.4	:	1.	FT	is	a	prodrug	of	FU,	
and	CDHP	competitively	inhibits	DPD	about	180	times	
more	effectively	than	uracil,	and	leads	to	the	retention	
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of	a	prolonged	concentration	of	FU	[30].	Therefore,	the	
administration	of	S-1	might	be	an	effective	strategy	for	
the	treatment	of	high	DPD-expressing	tumors	[31].
In	conclusion,	we	analyzed	the	relationship	between	
the	DPD	activity	and	the	sensitivity	to	in �i���	and	in �i��	
FU	chemosensitivity.	We	found	that	the	basal	level	of	
DPD	expression/activity	was	significantly	correlated	
with	FU	sensitivity	in	primary	breast	cancer.	DPD	is	a	
promising	molecular	marker	for	identifying	patients	for	
FU-based	and/or	s-1	based	chemosensitivity.	
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активность ДиГиДРоПиРиМиДин ДЕГиДРоГЕнаЗЫ 
коРРЕЛиРУЕт с ЧУвствитЕЛьностьЮ к фЛУоРоУРациЛУ 
ПРи РакЕ МоЛоЧноЙ ЖЕЛЕЗЫ 
Препарат ряда флуоропиримидина, флуороурацил (FU), я�ляет�я одним и�� наи�олее �а�то и�пол���уем��� ��имиоте-       
рапе�ти�е�ки�� препарато� паллиати�ной терапии �ол�н��� онкологи�е�кого профиля. Определение �иологи�е�ки�� 
факторо�, ��я��анн��� � �у��т�ител�но�т�ю ли�о � у�той�и�о�т�ю опу��олей к ��имиотерапе�ти�е�ким препаратам, 
� том �и�ле и к FU, я�ляет�я одним и�� наи�олее �а�н��� напра�лений клини�е�ки�� и��ледо�аний � онкологии.           
Цель: проанали��иро�ат� ���аимо��я��� ме�ду �нутриопу��оле��м уро�нем дигидропиримидин дегидрогена��� (DPD) 
и �у��т�ител�но�т�ю клеток к FU, по�кол�ку DPD я�ляет�я на�ал�н�м и лимитирую�им �н��имом � ката�оли��ме          
FU. Материалы и методы: определяли �у��т�ител�но�т� к препаратам � ги�токул�туре (histoculture drug response   
assay, HDRA) у ��� пациенто�. �к�пре��ия гена       DPD и��у�ена � ��� о�ра��це опу��оле�ой ткани �ол�н��� раком моло�ной 
�еле���, котор�м про�ели д�а цикла неоадъю�антной ��имиотерапии � применением FU. Результаты: пока��ано, �то 
�нутриопу��оле�ая акти�но�т� DPD о�ратно коррелирует � цитоток�и�но�т�ю FU. �ак�е ��я�лено, �то �ни�енная          
�к�пре��ия гена DPD коррелиирует � ���оким клини�е�ким от�етом на пер�и�ную ��имиотерапию, о�но�анную 
на FU. Выводы: ре��ул�тат� и��ледо�ания дают о�но�ание ��итат� DPD потенциал�н�м молекулярн�м маркером    
�у��т�ител�но�ти клеток ��лока�е�т�енн��� опу��олей моло�ной �еле��� к FU. 
Ключевые слова: флуороурацил, дигидропиримидин дегидрогена��а, рак моло�ной �еле���, �у��т�ител�но�т� к 
��имиотерапии.
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